Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 8/20 | 0.45 |
| ▸ | ACP1 | P24666 | 3/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27915294 | 0.83 | ALK (0.45) | SYKACP1EGFRRETSRC | |
| SCHEMBL2589911 | 0.82 | SYK (0.47) | SYKACP1MAPK1KDR | |
| SCHEMBL2587216 | 0.78 | NPC1 (0.43) | PKMRPS6KB1PLK4CHEK1MAPK13 | |
| SCHEMBL2588187 | 0.78 | METAP1 (0.40) | SYKROCK2PIM1PRKACACDK2 | |
| SCHEMBL14902607 | 0.74 | MEN1 (0.45) | PKMSYKMEN1NPC1KMT2A | |
| SCHEMBL2588865 | 0.74 | SYK (0.48) | SYK | |
| SCHEMBL22201437 | 0.70 | PRKCH (0.56) | SYKMAPK1NPC1 | |
| SCHEMBL2584861 | 0.70 | SYK (0.38) | SYKROCK2PIM1PRKACACDK2 | |
| SCHEMBL12385928 | 0.68 | SYK (0.49) | SYKMAPK1NPC1 | |
| SCHEMBL3280921 | 0.68 | CDC7 (0.48) | SYKFYNCDK1RETMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266879-B2 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTIC LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| EP-2563788-B1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE-INFLAMMATORY DISEASES | KARUS THERAPEUTICS LTD (GB) | 2015-08-05 | — | — | EP | disclosed |
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTICS LIMITED (UK) | 2013-05-02 | — | — | US | disclosed |
| CN-102985421-A | Naphthridine derivatives as pi3k inhibitors for the treatment of cancer and immune - inflammatory diseases | KARUS THERAPEUTICS LTD | 2013-03-20 | — | — | CN | disclosed |
| EP-2563788-A1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES | Karus Therapeutics Limited (GB) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011135351-A1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES | KARUS THERAPEUTICS LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | PIK3R5, PIK3CA, NFKBIA | PKM 2105/4885SYK 140/4885ACP1 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.